Malignant neoplasm of liver
|
0.590 |
PosttranslationalModification
|
disease |
BEFREE |
RESULTS The incidence of FHIT and p16 methylation in serum from the liver cancer group was 51.8% and 67.9%, respectively.
|
30773529 |
2019 |
Malignant neoplasm of liver
|
0.590 |
AlteredExpression
|
disease |
BEFREE |
The p16 protein expressions in liver cancer and para-carcinoma tissues were detected via immunohistochemistry (IHC), and the correlations of p16 positive expression with ultrasound parameters were also analyzed.
|
30509095 |
2019 |
Malignant neoplasm of liver
|
0.590 |
Biomarker
|
disease |
BEFREE |
These results are significant because they suggest that nucleolar p14ARF can be used as early prognostic marker in chronic liver disease to reliably identify patients with high risk for developing liver cancer.
|
29228217 |
2018 |
Malignant neoplasm of liver
|
0.590 |
Biomarker
|
disease |
CTD_human |
Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer.
|
27064257 |
2016 |
Malignant neoplasm of liver
|
0.590 |
Biomarker
|
disease |
BEFREE |
Yet Bmi1 functions independent of Ink4A/Arf repression in liver cancer development.
|
19934271 |
2009 |
Malignant neoplasm of liver
|
0.590 |
AlteredExpression
|
disease |
BEFREE |
Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer.
|
16317707 |
2005 |
Malignant neoplasm of liver
|
0.590 |
Biomarker
|
disease |
CTD_human |
Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer.
|
16317707 |
2005 |
Malignant neoplasm of liver
|
0.590 |
Biomarker
|
disease |
RGD |
Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer.
|
16317707 |
2005 |
Malignant neoplasm of liver
|
0.590 |
Biomarker
|
disease |
CTD_human |
Abnormalities of the ARF-p53 pathway in primary angiosarcomas of the liver.
|
12378512 |
2002 |
Malignant neoplasm of liver
|
0.590 |
Biomarker
|
disease |
RGD |
De novo methylation of the p16INK4A gene in early preneoplastic liver and tumors induced by folate/methyl deficiency in rats.
|
12359353 |
2002 |
Malignant neoplasm of liver
|
0.590 |
Biomarker
|
disease |
RGD |
Sequential changes in hepatocarcinogenesis induced by diethylnitrosamine plus thioacetamide in Fischer 344 rats: induction of gankyrin expression in liver fibrosis, pRB degradation in cirrhosis, and methylation of p16(INK4A) exon 1 in hepatocellular carcinoma.
|
11301474 |
2001 |
Malignant neoplasm of liver
|
0.590 |
GeneticVariation
|
disease |
BEFREE |
The purpose of the current investigation was to define the prevalence of genetic alterations in p16 and beta-catenin in NNK-induced rat liver cancer to determine if the molecular mechanisms seen in human tumors are the same in this animal model.
|
11238187 |
2001 |
Malignant neoplasm of liver
|
0.590 |
PosttranslationalModification
|
disease |
BEFREE |
Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients.
|
9892188 |
1999 |
Malignant neoplasm of liver
|
0.590 |
Biomarker
|
disease |
BEFREE |
Alterations of CDKN2 (MTS1/p16INK4A) gene in paraffin-embedded tumor tissues of human stomach, lung, cervix and liver cancers.
|
9873831 |
1998 |
Malignant neoplasm of liver
|
0.590 |
PosttranslationalModification
|
disease |
BEFREE |
Infrequent alterations of the p16INK4A gene in liver cancer.
|
8760583 |
1996 |